Dr. Walter D. Brown, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in Shreveport (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 520
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Louisiana State University School of Medicine in Shreveport
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
LA license 07368R -
Critical Care Medicine (Internal Medicine) Physician
LA license 07368R
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Lafayette General Medical Center Lafayette, LA
- Ochsner St Martin Hospital Breaux Bridge, LA
- Acadia General Hospital Crowley, LA
- Ochsner University Hospital and Clinics Lafayette, LA
- Ochsner American Legion Hospital Jennings, LA
Medical groups
- University Hospital and Clinics, Inc. (82 clinicians)
- Gbr, LLC (15 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 520
- Services billed
- 1,220
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 278 | 102 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 163 | 102 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 133 | 132 |
| Established patient office or other outpatient visit, 20-29 minutes | 113 | 90 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 71 | 46 |
| Test to determine lung volumes using sensors | 65 | 64 |
| Test to examine how well the lungs exchange gases | 64 | 63 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 41 | 41 |
| New patient office or other outpatient visit, 60-74 minutes | 41 | 41 |
| Test to measure expiratory airflow and volume | 28 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Lafayette, LA | 136 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Lafayette, LA | 114 |
| Azithromycin Other prescribers in Lafayette, LA | 69 |
| Montelukast Sodium Other prescribers in Lafayette, LA | 55 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Lafayette, LA | 41 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Lafayette, LA | 38 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Lafayette, LA | 35 |
| Wixela Inhub (fluticasone propion/salmeterol) Other prescribers in Lafayette, LA | 25 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Lafayette, LA | 23 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Lafayette, LA | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 109 payments worth $2,228 in total to this clinician.
| GlaxoSmithKline, LLC. | $492 |
|---|---|
| Genzyme Corporation | $426 |
| AstraZeneca Pharmaceuticals LP | $212 |
| Regeneron Healthcare Solutions, Inc. | $198 |
| Verona Pharma, Inc. | $159 |
| Insmed, Inc. | $125 |
| Viatris Specialty LLC | $109 |
| Grifols USA, LLC | $97.07 |
| Food and Beverage | $2,228 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.